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Ciprofloxacin versus levofloxacin in avoidance of prostate
biopsy in patients with isolated PSA elevation: a prospective
randomized study
Doğan ÜNAL1, Akif KOÇ2, Ömer Faruk KARATAŞ2, Ersin ÇİMENTEPE1

Aim: The efficiencies of ciprofloxacin and levofloxacin on prostate-specific antigen (PSA) elevation were compared in
terms of avoidance of prostate biopsy in this study.
Materials and methods: Included in the study were 43 men with PSA levels of ≥3.5 ng/mL. They were randomized into
either ciprofloxacin or levofloxacin groups for a 3-week course. PSA and free PSA levels were measured before and after
the antibiotherapy. The patients in whom PSA remained ≥3.5 ng/mL after therapy underwent biopsy.
Results: The average age of the men was 64.44 years (standard deviation: 9.54). Following antibiotics, 76.7% of the
patients showed a reduction in PSA and 32.6% showed PSA normalization; PSA levels dropped by a rate of 27.1% (P <
0.001). In the ciprofloxacin group, the PSA reduction rate and PSA normalization were insignificantly higher than in the
levofloxacin group. Ciprofloxacin caused a significant reduction in PSA (–41.6% change, P < 0.001), but levofloxacin did
not (–5.6% change). With quinolones, positive predictive value improved from 9.3% to 13.8%. Of the 29 patients with
persistent PSA levels of ≥3.5 ng/mL after antibiotics, 4 were diagnosed with prostate cancer (13.8%).
Conclusion: Empirical ciprofloxacin seems to be more effective than levofloxacin in men with isolated PSA elevation,
leading to the avoidance of unnecessary prostate biopsy in nearly half of the cases, and enhances diagnostic capabilities
of both PSA and prostate biopsy.
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Introduction
Prostate cancer (Pca) is estimated to be the most
common cancer, accounting for 1 of every 4 cancers,
and it was second highest in terms of the estimated
cancer deaths among men in 2008 (1). However,
diagnosing Pca accurately and precisely still remains
a challenge.
Diagnosis of Pca is ultimately made by transrectal
ultrasound (TRUS)-guided prostate biopsy (PB).
However, PB is moderately invasive and not easily
accepted by the patients. Furthermore, this procedure

may be complicated by hemorrhaging and infection or,
more seriously, by septicemia. To avoid unnecessary
or excessive PB, the diagnostic capabilities of other
important currently used diagnostic tools are being
augmented in various ways, such as prostate-specific
antigen (PSA) derivatives and contrast-enhanced
TRUS (2). However, the contribution of all of these
efforts to definite diagnosis continues to be debated.
On the other hand, prostatic inflammation may
be confused with Pca due to elevated PSA levels (37). In addition, diagnostic tools used for prostatitis
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cannot explicitly rule out Pca as being the definite
cause of elevated PSA (8-13). Therefore, various
antibiotherapies have been attempted to decrease PSA
and to avoid unnecessary biopsies. For this purpose,
in studies up until now, the effects of antibiotics
have been studied on PSA elevation in patients not
evaluated in terms of prostatitis or in those with
prostatitis diagnosed clinically or histopathologically
(5,8,14-17).
Although various antibiotics have been used to
decrease PSA, ciprofloxacin and levofloxacin have not
yet been sufficiently compared (Table 1) (5,8,9,11,1620). In this prospective randomized study, the
efficiencies of ciprofloxacin and levofloxacin were
compared in terms of decreasing PSA, and whether
attempts to diagnose prostatitis are absolutely
indicated to start antibiotherapy in isolated PSA
elevation was examined.
Materials and methods
A group of 50 men, with PSA levels of ≥3.5 ng/mL
and no suspicious findings in their digital rectal
examination (DRE), no urinary retention, no known
Pca, no prostatic surgery, and no urinary tract
infection signs in their clinical picture or urinalysis,
who were referred to the department of urology were
eligible to participate in our study.
Seven patients were excluded for either not
attending their follow-up appointment or for refusing
PB despite continued PSA elevation after antibiotics.
The remaining 43 patients were included in the study.
After informed consent was obtained, the patients
were randomized, according to their presenting
order, to 3 weeks of either 500 mg of ciprofloxacin
twice a day or 500 mg of levofloxacin once a day.
Total PSA and free PSA (fPSA) levels were
measured before and after the antibiotherapy.
Percent fPSA was presented as (fPSA / total PSA) ´
100. The patients with reduced PSA below 3.5 ng/mL
following antibiotics were considered as responding
to the antibiotics and did not undergo biopsy. These
cases were followed up with serial PSA measurements
and DRE at 3-month intervals. The patients in which
PSA levels remained at ≥3.5 ng/mL after therapy
underwent 12-core PB under TRUS guidance. PB
was done with the patient lying in the left lateral

decubitus position under antibiotic prophylaxis and
infiltrative local anesthesia. Pathological specimens
were routinely stained and examined.
Continuous variables given as medians (ranges)
were compared using the Mann-Whitney U test
for independent groups and with Wilcoxon test
for dependent groups, while categorical variables
were evaluated with Fisher’s exact test. P < 0.05 was
considered significant.
Results
The average patient age was 64.44 years (standard
deviation: 9.54). Of the 43 patients, 33 (76.7%)
showed a reduction in their PSA levels, and 14
(32.6%) showed PSA normalization following
antibiotics. Overall median PSA values were 6.90 ng/
mL (3.47-34.80) and 5.03 ng/mL (1.09-27.03), preand posttreatment, respectively (27.1% reduction, P
< 0.001). Overall median %fPSA values decreased
from 17.22 ng/mL (7-44.2) to 16.84 ng/mL (4.2-35.4)
following antibiotics (2.2% change, P = 0.456).
In the ciprofloxacin group, the rate of PSA
reduction was higher than in the levofloxacin
group (90% and 65.2%, respectively; P = 0.058).
Likewise, the PSA normalization rate obtained using
ciprofloxacin was insignificantly higher compared to
levofloxacin (45% vs. 21.7%, respectively; P = 0.097)
(Table 2).
Ciprofloxacin caused a statistically significant
reduction in PSA values (6.7 ng/mL to 3.91 ng/mL,
–41.6% change; P < 0.001), but with levofloxacin,
an insignificant reduction was obtained in PSA
values (6.96 ng/mL to 6.57 ng/mL, –5.6% change,
P = 0.132). Although the increase in %fPSA after
ciprofloxacin was found to be higher than after
levofloxacin, the changes before and after treatment
for both drugs were insignificant (P = 0.463 and P =
0.778, respectively) (Table 3).
Of the 29 patients with persistent PSA values of
≥3.5 ng/mL after antibiotics, 4 were diagnosed with
Pca (13.8%) (Table 4). In other words, the positive
predictive value (PPV) improved from 9.3% (4/43)
to 13.8% (4/29) following quinolones. In 3 of the 4
cancer patients, a decrease in their PSA values was
found after antibiotherapy (Table 5).
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Table 1. Response criteria according to drop in PSA, the rates of patients with decreased and normalized PSA, the rates of decrease in PSA levels, the criteria used in deciding
biopsy, and the rates of prostate cancer diagnosed under and over cutoff following antibiotherapy in patients with elevated PSA in some investigations.
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Table 2. The number of patients whose PSA levels (%) decreased or increased generally and those whose decreased below or remained
above 3.5 ng/mL after antibiotherapy according to quinolone types.
Ciprofloxacin

Levofloxacin

Total

P*

Pts with decreased PSA

18 (90.0)

15 (65.2)

33 (76.7)

0.058

Pts with increased PSA

2 (10.0)

8 (34.8)

10 (23.3)

Total

20 (100)

23 (100)

43 (100)

Pts with PSA of <3.5 ng/mL

9 (45.0)

5 (21.7)

14 (32.6)

Pts with PSA of ≥3.5 ng/mL

11 (55.0)

18 (78.3)

29 (67.4)

Total

20 (100)

23 (100)

43 (100)

*According to chi-square, Fisher’s exact test.

0.097

Pts, patients.

Table 3. The comparisons between baseline and posttreatment median values (ranges) of PSA and %fPSA in the quinolone groups.
Ciprofloxacin
(n = 20)

Levofloxacin
(n = 23)

Total
(n = 43)

P**

Baseline PSA

6.70 (3.47-34.80)

6.96 (4.16-15.16)

6.90 (3.47-34.80)

0.670

Posttreatment PSA

3.91 (1.09-11.85)

6.57 (1.33-27.03)

5.03 (1.09-27.03)

0.008

Change (%)

–41.6

–5.6

–27.1

P*

<0.001

0.132

<0.001

Baseline %fPSA

18.10 (7.30-44.20)

16.34 (7.00-38.50)

17.22 (7.00-44.20)

0.313

Posttreatment %fPSA

21.49 (4.50-35.40)

16.47 (4.20-30.60)

16.84 (4.20-35.40)

0.138

Change (%)

+18.7

+0.8

–2.2

P*

0.463

0.778

0.456

*According to Wilcoxon test.

**According to Mann-Whitney U test.

Table 4. Pathological diagnoses of the patients undergoing TRUS-guided prostatic
needle biopsy due to continued PSA values equal to or higher than 3.5 ng/mL
after antibiotherapy.
Diagnosis

n

%

Benign prostatic hyperplasia (BPH)

20

68.9

Prostatic adenocarcinoma

4

13.8

BPH + prostatitis

3

10.3

BPH + prostatitis + ASAP

1

3.5

BPH + prostatitis + PIN (low)

1

3.5

Total

29

100.0

ASAP, atypical small acinar proliferation; PIN, prostatic intraepithelial neoplasia.
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Table 5. The changes of PSA levels after antibiotherapy in patients with prostatic adenocarcinoma.
Baseline PSA values (ng/mL)

PSA values after antibiotics (ng/mL)

Case 1

5.83

4.73

Case 2

15.16

10.01

Case 3

4.76

4.93

Case 4

6.96

5.78

In subjects with decreased PSA, malignancy was
not found to be lower (P = 0.571) (Table 6). Likewise,
PSA changes were not significantly different
between malignant and benign groups. However,
the posttreatment median %fPSA was significantly
higher in the benign group (P = 0.034) (Table 7).

The numbers of patients with decreased/increased
PSA were not different between benign groups (Table
8). Changes of PSA and %fPSA were also similar
between benign groups, except for significant PSA
decrease in the benign prostatic hyperplasia (BPH) +
prostatitis group (P = 0.043) (Table 9).

Table 6. The number of patients (%) with decreased and increased PSA values after antibiotherapy according to
malignant and nonmalignant prostatic histopathology.
Malignant

Nonmalignant

Total

P*

Pts with decreased PSA

3 (75)

16 (64)

19 (66)

0.571

Pts with increased PSA

1 (25)

9 (36)

10 (34)

Total

4 (100)

25 (100)

29 (100)

*According to chi-square, Fisher’s exact test.
Pts, patients.

Table 7. Median values (ranges) of PSA and %fPSA before and after antibiotherapy in the patients with malignant and nonmalignant
prostatic histopathology.
Malignant (n = 4)

Nonmalignant (n = 25)

Total

P**

Baseline PSA

6.39 (4.76-15.16)

8.48 (4.09-34.80)

7.68 (4.09-34.80)

0.562

Posttreatment PSA

5.36 (4.73-10.01)

6.56 (3.52-27.03)

5.79 (3.52-27.03)

0.444

Change (%)

–16.1

–22.6

–24.6

P*

0.144

0.143

0.064

Baseline %fPSA

12.39 (7.00-17.50)

20.24 (8.60-44.20)

17.75 (7.00-44.20)

0.122

Posttreatment %fPSA

11.68 (8.40-16.50)

18.00 (4.50-35.40)

16.82 (4.50-35.40)

0.034

–5.7

–11.1

–5.2

1

0.472

0.543

Change (%)
P*
*According to Wilcoxon test.
**According to Mann-Whitney U test.
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Table 8. The number of patients (%) with decreased and increased PSA values after antibiotherapy according to benign
prostatic histopathology.
BPH

BPH + prostatitis

Total

P*

Pts with decreased PSA

11 (55)

5 (100)

16 (64)

0.082

Pts with increased PSA

9 (45)

0 (0)

9 (36)

20 (100)

5 (100)

25 (100)

Total

*According to chi-square, Fisher’s exact test.
Pts, patients.

Table 9. Median values (range) of PSA and %fPSA before and after antibiotherapy in the patients with benign prostatic
histopathology.

Baseline PSA

7.69 (4.09-25.11)

BPH + prostatitis
(n = 5)
11.2 (4.50-34.80)

Posttreatment PSA

6.68 (4.30-27.03)

4.74 (3.52-11.90)

6.56 (3.52-27.03)

Change (%)

–13.1

–57.7

–22.6

P*

0.526

0.043

0.143

Baseline %fPSA

22.49 (9.00-38.50)

12.93 (8.60-44.20)

20.24 (8.60-44.20)

0.208

Posttreatment %fPSA

18.75 (8.40-35.40)

16.81 (4.50-21.50)

18.00 (4.50-35.40)

0.290

Change (%)

–16.6

+30.0

–11.1

P*

0.311

0.686

0.472

BPH (n = 20)

Total

P**

8.48 (4.09-34.80)

0.530
0.071

*According to Wilcoxon test.
**According to Mann-Whitney U test.

Discussion
The main pathologies responsible for elevated
PSA are Pca, BPH, and prostatitis (15,18,21). These
conditions can commonly share the same clinical
symptoms, or occasionally cause no symptoms. In
contrast to BPH and category I prostatitis as defined
by the National Institutes of Health (NIH I), the
effects of prostatitis NIH II, III, and IV on PSA are
somewhat controversial. In fact, although it has been
stated that prostatitis NIH III and IV do not cause
any significant elevation in PSA, it has been generally
considered that all categories of prostatitis can lead to
a notable rise in PSA (3-7,22,23). For instance, it has
been claimed that Pca and NIH IV prostatitis have
similar effects on PSA (24).
Immediate PB, particularly in men with
moderately elevated PSA, is not considered justified

by many urologists. In fact, in the first instance of
elevated PSA, instead of immediate PB it is advised
that PSA tests should be repeated after a few weeks
under similar and optimal conditions as defined in
the European Association of Urology guidelines (2a
evidence level) (25). Moreover, of the subjects with
normal DRE results and elevated PSA levels between
4.1 and 10 ng/mL, 80% are diagnosed as benign in
their biopsy specimens (26). Therefore, it seems
logical to repeat PSA tests or to rule out prostatitis
before PB to preclude unnecessary biopsies (4,9,25).
Prostatitis can be diagnosed histopathologically
and/or with a conventional 4-glass test, but the role
of symptom indexes in diagnosis is controversial
(27). Additionally, can antibiotics be used as a way to
avoid unnecessary biopsies in PSA-elevated patients?
Indeed, initial antibiotherapy may be attractive,
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particularly in cases where patients are willing to
postpone their biopsies. Furthermore, the change
in PSA after antibiotics was offered as a diagnostic
method in men with elevated PSA levels and normal
DREs (5,16). In such patients, antibiotherapy has
been justified only after proven histological prostatitis
or after performing an expressed prostatic secretion
(EPS) test; it is not cost-effective in category IV and is
not indicated in category III prostatitis (3).
However, in a study of Kaygisiz et al., because
no relation was found between the existence of
inflammation in the prostatic massage and the effect
of antibiotics on PSA, the authors suggested that
antibiotherapy can be given without inflammation
being found before biopsy (8). The authors
suggested that biopsy can be avoided in another
18.8% if antibiotics are also given to EPS-negative
men, reaching a biopsy avoidance rate of 37.5%
(8). Similarly both Serretta et al. and Chang et al.
also found no correlation between PSA values and
histological score, and Potts noted positive culture
in 55% of the Pca patients with abnormal PSA
levels after antibiotics, although there were authors
advocating the contrary (9-11,28). In this instance, in
a patient with lower inflammatory status but higher
PSA levels, EPS testing may not be conclusive, and
an unnecessary biopsy could be done. In fact, the
clinical usefulness of a 4-glass test has been forcefully
questioned (12,13). According to Nickel et al., only
32% of patients with chronic prostatitis/chronic
pelvic pain syndrome, versus 20% of the controls,
had 10 white blood cells per high-power field in EPS
(13). Additionally, the EPS test is only an indirect test
and cannot directly point out and identify bacteria. In
other words, a 4-glass test can yield an unacceptable
false-negative outcome in addition to the expense
and the somewhat uncomfortable aspects of prostatic
massage for the patients (11). Thus, some investigators
have used antibiotics regardless of EPS before biopsy
in patients with elevated PSA levels (3,14,15,17)
Consequently, in spite of the potential risk
for bacterial resistance and resultant infective
complications, empirical antibiotic management
seems logical, since antibiotics will already be given
in a case with a positive EPS test and can be given
in a subject with a negative test due to the fact that
inflammation cannot be ruled out completely (29).
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PSA normalization after empirical antibiotics,
therefore, might feasibly show prostatic inflammation
and avoid an unnecessary biopsy, as well.
Many studies have shown that antibiotics
actually reduce PSA levels in patients who would
be otherwise be candidates for PB (5,8,9,11,16-19).
In these studies, quinolones were much more widely
used, probably due to their efficacy against gramnegative bacteria found in higher concentration
levels in the prostate and urine; 55% to 82% of the
patients showed a decrease in PSA and 8% to 60%
showed PSA normalization. Additionally, PSA levels
significantly decreased after antibiotics by a rate of
11% to 36% (Table 1) (8,16-19,30). Consistently in the
literature we found a PSA decrease of 77% and PSA
normalization in 33% of patients after antibiotics.
Posttreatment PSA levels were significantly lower by
a rate of 27%.
In the literature, only scarce studies comparing
ciprofloxacin with levofloxacin have been published
(9,17,18). In our comparative study, ciprofloxacin
significantly reduced PSA levels from 6.7 ng/mL to
3.91 ng/mL, while levofloxacin did not. However,
although the percentage of patients whose PSA
levels decreased or normalized was higher in the
ciprofloxacin group, this difference was statistically
hardly significant. In other investigations, no
correlation was observed among serum PSA levels
and type and duration of quinolone, and no difference
was found between levofloxacin and ciprofloxacin in
terms of lowering PSA and treating chronic bacterial
prostatitis (5,17,20). However, Schaeffer et al. noted
that a little more microbiological eradication was
obtained with ciprofloxacin in subjects whose PSA
normalized after therapy compared to levofloxacin
(93.3% and 90.9, respectively) (5).
Percent fPSA insignificantly increased after
quinolones, although the change was little higher
in the ciprofloxacin group than in the levofloxacin
group (19% vs. 0.8%, respectively) in our study. In
other studies, an increase in %fPSA of between 0.5%
and 14% was seen (8,9,17,18). Kaygisiz et al. found
this rise to be statistically significant, but others
considered it insignificant, like our study. However,
in our series, posttreatment %fPSA values were
significantly higher (P = 0.034) in nonmalignant
cases than in malignant ones, which should suggest
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that antibiotics could enhance the diagnostic power
of %fPSA. Similarly, in a study by Dirim et al., the
increased ratio of fPSA to total PSA was more evident
in benign cases (17).
We diagnosed 4 cases of Pca among the 29 patients
(13.8%) whose PSA values remained over cutoff after
quinolones. We found that 3 of the 4 patients with
malignancy had decreased PSA levels after antibiotics,
although there was no significant difference between
malignant and nonmalignant cases in terms of
the patients whose PSA level increased/decreased
and the change of PSA after antimicrobial therapy.
Similarly, Kaygisiz et al. found this rate to be 2 out
of 4 patients with malignancy (8). In other words, we
determined 1 case of cancer among 10 patients (10%)
with increased PSA, and 3 cases of cancer among 19
patients (15.8%) with decreased PSA. The difference
between these rates was insignificant. On the
contrary, Serretta et al. found a significant difference
(P = 0.02) (9). In fact, they diagnosed Pca in 40% of
the cases with increased or unchanged PSA and in
20.3% of the patients with reduced PSA (9).
We did not require PB in patients showing
PSA normalization. Likewise, many investigators
performed no biopsy for men with reduced PSA
levels below the cutoff value after antibiotics (11,1719). However, although some authors preferred
to do a biopsy for all patients even if they had
PSA normalization after treatment, most of them
diagnosed no cancer in patients with normalized
PSA levels (8,9).
Additionally, in our study, PSA levels reduced
by a rate of 16.1% in malignant and 22.6% in
benign pathology, although this was considered
insignificant. Similarly, the 4.8% decrease of PSA in
malignant cases after therapy found by Bozeman et
al. was insignificant (19). However, the authors found

that a 52.2% decrease of PSA levels in patients with
nonmalignant pathology was significant, contrary to
our findings.
On the other hand, our finding of significant
PSA reductions in the BPH + prostatitis group could
indicate a mechanism by which antibiotherapy
can decrease the need for a biopsy in patients with
elevated PSA. In the same way, Magri et al. noted
higher PSA reduction rates in the patients with the
pathology of prostatitis without BPH when compared
to those with the BPH pathology only (30).
In our clinical study, we noted that ciprofloxacin
prevented PB in 9 patients (45%) and levofloxacin
in 5 patients (21.7%), a total of 14 patients (32.6%),
although this was considered statistically insignificant.
In other words, with quinolones, the PPV estimated
in our study improved from 9.3% (4/43) to 13.8%
(4/29). In fact, in various studies, PPVs rose from
7%-32% to 11%-85% after antibiotics (8,9,11,16-19).
These findings suggest that empirical ciprofloxacin
can preclude unnecessary biopsies more effectively
than levofloxacin. In addition, patients with
histopathological prostatitis respond much better
to antibiotics, constituting the rationale underlying
antibiotic treatment in PSA elevation. Management
of patients showing moderately elevated PSA with
quinolones seems to be reasonable due to the fact that
they are well tolerated and have mostly acceptable
side effects (9,20).
Empirical ciprofloxacin seems to be more effective
than levofloxacin in men with isolated PSA elevation,
leading to the avoidance of unnecessary PBs in
nearly half of the cases, and enhances the diagnostic
capability of PSA, although continued studies with
larger series and long-term outcomes should be
conducted.
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